Company Updates covers news from Brilliant Blue Biosciences. Research & Industry News highlights relevant developments published by external sources, summarised and attributed to them.
MIT News reports a two-stage process that measures lipid nanoparticle size during production and uses the resulting data to guide processing conditions for RNA-therapy development. The team is pursuing commercialisation through BIZON Labs; no clinical testing is reported.
Rznomics says its participation in Lilly Gateway Labs is intended to accelerate discovery and development of RNA therapeutic candidates. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Wacker is expanding contract research to include RNA and plasmid construct design alongside its existing RNA, pDNA and LNP formulation activities. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →ParcelBio announced a programmable mRNA platform and $13 million in financing for its emerging therapeutic pipeline. The announcement concerns a product, collaboration or production plan; it does not by itself establish clinical benefit or verified scale-up performance.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →GEN reviews the translation of nonviral gene-delivery platforms, including lipid and polymer-based approaches. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Research reporting describes modified LNPs intended to improve delivery of mRNA cargo to lymph nodes. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →GEN reports an amino-acid formulation approach intended to improve LNP delivery for mRNA and CRISPR cargo. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →GEN reports research linking internal lipid-nanoparticle structure with cargo delivery inside cells. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →GEN reports development of lipid nanoparticles designed to deliver nucleic-acid cargo to lung and eye tissues. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →A two-step microfluidics system created ternary nano-scale lipopolyplexes, using polymer choice to determine the lipopolyplexes’ structure, which affects vector size and distribution. This overcomes barriers to manufacturing and creates nonviral vectors for efficient DNA delivery. The post Microfluidics-Manufactured Lipopolyplexes Offer Size Consistency appeared first on GEN - Genetic Engineering The report concerns nonviral delivery, nanocarrier development, formulation, or translation; it does not by itself establish clinical benefit.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →A close partnership between academic institutions, industry, and the FDA is necessary for success in manufacturing personalised treatment. That’s a key message behind a talk at BPI this week, presented by Max Sellman of Aldevron. The post Collaboration Key to First Personalised mRNA-based CRISPR Therapy appeared first on GEN - Genetic Engineering and Biotechnology News. The report concerns nonviral delivery, nanocarrier development, formulation, or translation; it does not by itself establish clinical benefit.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →GEN reports research on a polymer-based alternative to PEG in lipid nanoparticles for mRNA delivery. The report does not by itself establish clinical benefit or clinical efficacy.
Source: GEN — Genetic Engineering & Biotechnology News
Read more →We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.
Prefer to talk it through? Book a 30-minute discovery call
